A simple clinical test is being developed for use in diagnosing patients with chronic and acute BLOS. Currently, Flow Cytometry is the only method to measure the %ROS-positive blood cells, but the estimated cost is greater than $500/sample. The BLOS# method provides the same information as the Flow Cytometry method at a fraction of the cost (see table below). Compared to tests available for diagnosing diabetes, the laboratory cost of the BLOS# method is comparable. The three conventional diagnostic methods evaluate symptoms of diabetes (AIC, plasma glucose, oral glucose), while the BLOS# method evaluates the causative agent (ROS-positive blood cells). It is anticipated that the BLOS# method will be approved as a Lifestyle choice and then a Disease Diagnostic, which will make it the preferred blood test for evaluating human health. The BLOS# method may also be part of a new, comprehensive approach for Personalized Medicine.
The BLOS# method uses a simple laboratory protocol that compares ROS production of the sample to a maximally induced subsample. Raw sample data is processed by a proprietary and patent-pending algorithm that is integrated in software hosted on a cloud server. The BLOS# value is calculated from the input data and provided to the Medical Laboratory and subsequently to the physician and patient.
Non-Provisional U.S. Patent Application is currently in review
Title: Methods and Systems for Controlling Oxidative Stress in Humans and Animals
The Patent (pending) was assigned to Western Autotroph Company LLC DBA HemaGnosis.
The USPTO announced that the BLOS# patent application will be allowed and a patent issued in the coming weeks.
HemaGnosis started a new Crowdfunding campaign to raise $17,000 needed for a pilot-study conducted by Colorado State University. This pilot-study will evaluate the new BLOS# test for patients that are normal weight, overweight, and Type 2 Diabetics. Rewards include a free future FDA approved BLOS# test with donations of $25 or more. Use the following link to make a donation:
Glixin (formerly HemaGnosis) formalized an agreement with Colorado State University for a limited Pilot Study that should be starting in January 2020.